Market Place
News Type
Upload your Marketing & Sales content on your company Virtual Booth, click HERE
X
Developments Neurology Phase II
Japan 
Details:
KW-6356 is a selective antagonist of adenosine A2A receptors developed by Kyowa Kirin, however the company decided to discontinue its phase 2 trial after through evaluation of global regulatory landscape & potential timelines for market entry.
Lead Product(s): KW-6356,Levodopa
Therapeutic Area: Neurology Product Name: KW-6356
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable July 15, 2022
Details:
Under this agreement, Kissei grants Affamed the exclusive right for development and commercialization in China, Taiwan, Hong Kong, Macao and six Southeast Asian countries (Singapore, Malaysia, Thailand, Indonesia, Vietnam, and Philippines.
Lead Product(s): KDT-3594
Therapeutic Area: Neurology Product Name: KDT-3594
Highest Development Status: Phase II Product Type: Undisclosed
Partner/Sponsor/Collaborator: Affamed
Deal Size: Undisclosed Upfront Cash: Undisclosed
Deal Type: Licensing Agreement October 09, 2020
Details:
Primary endpoint achieved, demonstrating a statistically significant reduction of seizures from baseline compared to placebo in the combined Dravet syndrome and Lennox-Gastaut syndrome study population.
Lead Product(s): Soticlestat
Therapeutic Area: Neurology Product Name: TAK-935
Highest Development Status: Phase II Product Type: Small molecule
Partner/Sponsor/Collaborator: Ovid Therapeutics
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable August 25, 2020
